Monitoring melanoma immunotherapeutic efficacy through successive metabolic labeling and PD-L1-confined signal amplification based on membrane characteristics of the newly generated circulating tumor cells
- 20 March 2025
- journal article
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 280, 117403
Abstract
No abstract availableKeywords
Funding Information
- Sichuan University
- National Natural Science Foundation of China (32471524)
This publication has 26 references indexed in Scilit:
- Bioorthogonal Microbubbles with Antifouling Nanofilm for Instant and Suspended Enrichment of Circulating Tumor CellsACS Nano, 2023
- Self-calibrated magnetic aptamer sensor with dual Lanthanide-assisted Time-resolved luminescence for high-sensitive detection of melanoma exosomal PD-L1Materials & Design, 2023
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeCell, 2021
- Cell‐Released Magnetic Vesicles Capturing Metabolic Labeled Rare Circulating Tumor Cells Based on Bioorthogonal ChemistrySmall, 2021
- A Theranostic Cellulose Nanocrystal‐Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of MelanomaSmall, 2021
- Clinical Challenges of Immune Checkpoint InhibitorsCancer Cell, 2020
- Ultrasensitive Detection of Circulating Tumor DNA of Lung Cancer via an Enzymatically Amplified SERS-Based Frequency Shift AssayACS Applied Materials & Interfaces, 2019
- The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and ImmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapyNature Reviews Cancer, 2016
- Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assayNature Biotechnology, 2013